Compliance
★    

India,
2012-05-31 14:20
(4746 d 17:28 ago)

Posting: # 8642
Views: 4,226
 

 Expected LOQ [Bioanalytics]

Dear All,

Don't it possible for FDA to give some light about the LLOQ requires for method in OGD recommendation.

Might be you laugh loudly on my question but my curiosity push me to ask this to you.

Regards,

Compliance


Edit: Category changed. [Helmut]
ElMaestro
★★★

Denmark,
2012-05-31 15:31
(4746 d 16:17 ago)

@ Compliance
Posting: # 8643
Views: 3,508
 

 Expected LOQ

Hi Comp,

❝ Don't it possible for FDA to give some light about the LLOQ requires for method in OGD recommendation.


I am not exactly sure what you mean but in my opinion the LLOQ in itself is not always king. Often it is, and often companies strive to get it as low as possible but other factors weigh heavily in when it comes to judging if an assay is good enough.
1. As a rule of thumb Cmax should be at least 20x the LLOQ. If it isn't then the problem may not be the assay but something else, such as the subject or the clinic; or there might not be a problem at all anyway.
2. Subjects can be dosed 2, 3, 4... tablets per period if need be. In certain types of BE studies the dose should reflect a high tolerable dose anyway in which cases the LLOQ might be a relatively pointless parameter to improve.
3. An LLOQ may depend on the matrix. Forcing a specific LLOQ onto a lab could imply less freedom in the choice between e.g. plasma or serum. Traditionally both are generally acceptable, as far as I can tell.
4. A high LLOQ in combo with good general GLP compliance is in all likelihood preferable to a low LLOQ with bad general GLP compliance. These things are however never crystal clear. For example, old chromatographic columns often give much more baseline noise than new columns. So one might say that in evaluating signal-to-noise and making the choice about LLOQ one should be conservative and use old columns. Or go even further into the extreme and say it is a potential GLP violation to use only new columns when evaluating S/N and LLOQ and such. But this is solely an interpretation since there is no specific GLP clause that dictates anything about the LLOQ.
(I am sure there are at least 50 other things to mention here).

So all in all I would say the LLOQ, while often a very important indicator of assay performance, is on its own not a good single indicator to base decisions on and pt. 1 vs. pt. 4 illustrates how the LLOQ can be both a very objective performace indicator as well as one that involves subjectivity. This is just my humble and unqualified opinion and I'd love to hear input from others here.

Pass or fail!
ElMaestro
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2012-05-31 19:07
(4746 d 12:41 ago)

@ ElMaestro
Posting: # 8645
Views: 3,520
 

 (L)LOQ only part of the story

Hi ElMaestro & Compliance!

❝ […] in my opinion the LLOQ in itself is not always king. Often it is, and often companies strive to get it as low as possible but other factors weigh heavily in when it comes to judging if an assay is good enough.


Well said! Remember that one? No need to go ‘as low as possible’ (as ýou stated in your #1).
Methods used for quantitative measurement [of analytes in any given biological matrix] must be
  1. reliable and reproducible
  2. for the intended use.
#1 is the usual stuff (accuracy, precision, selectivity/sensitivity, reproducibility, stability, :blahblah:), but very important is #2 (working range: LLOQ ≤5% Cmax - carry-over, ULOQ ≈Cmax*, AUCt/AUC ≥80%).

❝ 3. […] plasma or serum. Traditionally both are generally acceptable, as far as I can tell.


Right. But if ever possible analysts would opt for plasma. There’s a manifold of problems to be expected with serum:
  • Requires sufficient time for clotting – no cooling allowed. Analyte must be stable / stabilized.
  • Potential problems after thawing. Turbidity may require centrifugation – does the lab have a cooled centrifuge?
  • Sometimes problems become evident only in multiple freeze-thaw-cycles. This is part of validation, but not necessarily of method development. I have seen surprises here.
If I see a method in serum I ask myself (well, and the analyst) why this matrix was chosen. The only excuse would be that none of the available anticoagulants ‘worked’.

Ad #4: Sometimes new columns show bad performance. They need some run-in / conditioning (adsorption of matrix components) to work within specs (resolution, peak shape, k’, Rs, …). Not so few analysts keep wonder-columns in a drawer labeled ‘Only for method X – don’t touch!’.


  • Never use the mean Cmax from literature. Try to set the ULOQ in such a why that you ‘catch’ all subjects’ Cmax. Validate dilution with matrix; needed if a value is outside the working range.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Compliance
★    

India,
2012-06-01 12:54
(4745 d 18:54 ago)

@ Helmut
Posting: # 8649
Views: 3,417
 

 (L)LOQ only part of the story

Dear Both,

Thank you very much for your detailed response. I have ask this because i had few things in my mind as mentioned below.

1. We can quantify maximum time points instead of getting BLQ in initial and at elimination level which help us to calculate AUC properly.
2. Minimize repetition due to dilution and modification or re construction of curve after initial analysis.

Anyways again thank you very much for your response.


Regards,

Compliance
UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,678 registered users;
100 visitors (0 registered, 100 guests [including 9 identified bots]).
Forum time: 07:48 CEST (Europe/Vienna)

If you want to get people to believe
something really, really stupid,
just stick a number on it.    Charles Seife

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5